Old Web
English
Sign In
Acemap
>
authorDetail
>
Phyllis Potts
Phyllis Potts
Dexamethasone
Bortezomib
Immunology
Medicine
Multiple myeloma
3
Papers
115
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
2010
British Journal of Haematology
William Bensinger
Sundar Jagannath
Robert Vescio
Elber S. Camacho
Jeffrey L. Wolf
David M. Irwin
Gerardo Capo
Marti McKinley
Phyllis Potts
David H. Vesole
Amitabha Mazumder
John Crowley
Pam Becker
Jacqueline Hilger
Brian G. M. Durie
Show All
Source
Cite
Save
Citations (36)
Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
2009
British Journal of Haematology
Sundar Jagannath
Brian G. M. Durie
Jeffrey L. Wolf
Elber Camacho
David M. Irwin
Jose Lutzky
Marti McKinley
Phyllis Potts
Afshin Eli Gabayan
Amitabha Mazumder
John Crowley
Robert Vescio
Show All
Source
Cite
Save
Citations (53)
A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
2007
Blood
William Bensinger
Sundar Jagannath
Robert Vescio
Elber S. Camacho
Jeffrey L. Wolf
D. Irwin
Gerardo Capo
Marti McKinley
Phyllis Potts
David H. Vesole
Amitabha Mazumder
Dixie-Lee Esseltine
Pamela S. Becker
John Crowley
Brian G. M. Durie
Show All
Source
Cite
Save
Citations (26)
1